Kura Oncology, Inc.
(NASDAQ : KURA)

( )
KURA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.83%88.651.3%$855.17m
BIIBBiogen Inc.
1.02%222.501.3%$586.68m
AMGNAmgen Inc.
-0.06%186.591.2%$533.06m
ONCESpark Therapeutics, Inc.
0.47%113.5311.2%$497.94m
GILDGilead Sciences, Inc.
0.03%63.790.9%$468.70m
REGNRegeneron Pharmaceuticals, Inc.
0.82%395.002.6%$283.62m
ILMNIllumina, Inc.
-1.65%303.713.5%$275.40m
VRTXVertex Pharmaceuticals Incorporated
1.28%183.851.9%$247.78m
SRPTSarepta Therapeutics, Inc.
-2.73%118.9215.4%$216.64m
BPTHBio-Path Holdings, Inc.
-12.42%19.25190.1%$203.41m
ALXNAlexion Pharmaceuticals, Inc.
1.60%132.292.0%$187.73m
EXASExact Sciences Corporation
0.07%89.0625.3%$173.12m
AAgilent Technologies, Inc.
0.66%79.511.6%$122.76m
IONSIonis Pharmaceuticals, Inc.
0.18%79.048.3%$109.28m
INCYIncyte Corporation
0.80%86.022.5%$93.70m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.